drugset / Trial / NCT03251612
Predictive Value of Drug Sensitivity Testing Tumorspheres From Patients With Metastatic Colorectal Cancer
NaSingle-groupOpen-labelTreatment
Summary
The purpose of the present study is to investigate the benefit of anti-cancer therapy administered on the basis of drug sensitivity testing. This concerns colorectal cancer patients who have previously received standard treatment.
Timeline
- Start
- 2017-09-22
- Primary completion
- 2021-08-23
- Completion
- 2022-03-21
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | — | — |
| Subject | Capecitabine | Small molecule | — | — |
| Subject | Cetuximab | Monoclonal antibody | — | — |
| Subject | Irinotecan | Small molecule | — | — |
| Subject | Oxaliplatin | Small molecule | — | — |
| Subject | Panitumumab | Monoclonal antibody | — | — |
| Subject | Regorafenib | Small molecule | — | — |
| Subject | TAS-102 | Small molecule | — | — |
| Subject | fluorouracil | Small molecule | — | — |